Literature DB >> 22992699

DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.

Yong H Wen1, Edi Brogi, Zhaoshi Zeng, Muzaffar Akram, Jeff Catalano, Philip B Paty, Larry Norton, Jinru Shia.   

Abstract

Recent studies have suggested that breast cancer is part of the tumor spectrum in Lynch syndrome (LS). However, the frequency and significance of DNA mismatch repair (MMR) deficiency in breast carcinoma in general is unclear. Some triple-negative breast carcinomas (TNBCs) have morphologic features similar to those described in LS-associated colorectal carcinomas; therefore, we hypothesized that TNBCs might be more likely to have MMR deficiency. In this study, we tested our hypothesis in a series of 226 TNBCs along with a control series of 90 non-triple-negative tumors, utilizing DNA MMR protein immunohistochemistry followed by PCR microsatellite instability testing and MLH1 promoter methylation testing. By immunohistochemistry, we identified 4 triple-negative carcinomas (4/226, 1.8%) showing loss of MMR proteins (3 lost MLH1 and PMS2, and 1 lost MSH2 and MSH6); whereas none of the 90 non-triple-negative carcinomas showed loss of protein. Further testing of the 3 MLH1/PMS2 protein-deficient carcinomas identified 1 tumor showing high-frequency microsatellite instability and MLH1 promoter hypermethylation. All 4 MMR protein-deficient carcinomas were ductal type with high histologic and nuclear grades. Prominent lymphocytic infiltration was noted in 2 tumors. The clinical characteristics and survival outcome varied widely among the 4 patients. In conclusion, our results suggest that DNA MMR deficiency is rare in breast carcinoma, and as such, testing of breast carcinoma for the detection of LS may best be restricted to high-risk individuals only. Our data also suggest that not all MMR protein-deficient breast tumors show microsatellite instability, and MLH1 promoter methylation is the molecular basis for at least a subset of microsatellite instable breast tumors. Although MMR-deficient breast carcinomas share certain morphologic features with the more typical types of LS-associated tumors, better characterization, and a better understanding of their clinical behavior await further analysis with a larger sample size.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22992699     DOI: 10.1097/PAS.0b013e3182627787

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

Review 1.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

2.  Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.

Authors:  M Aravind Kumar; Shaik Mohammad Naushad; Narasimhulu Narasimgu; S Nagaraju Naik; Srilatha Kadali; Uday Shanker; M Lakshmi Narasu
Journal:  Mol Biol Rep       Date:  2018-08-22       Impact factor: 2.316

3.  Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.

Authors:  Christopher J Schwartz; Edaise M da Silva; Antonio Marra; Andrea M Gazzo; Pier Selenica; Vikas K Rai; Diana Mandelker; Fresia Pareja; Maksym Misyura; Timothy M D'Alfonso; Edi Brogi; Pamela Drullinsky; Pedram Razavi; Mark E Robson; Joshua Z Drago; Hannah Y Wen; Liying Zhang; Britta Weigelt; Jinru Shia; Jorge S Reis-Filho; Hong Zhang
Journal:  Clin Cancer Res       Date:  2021-10-19       Impact factor: 13.801

4.  DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.

Authors:  Marie Ollier; Nina Radosevic-Robin; Fabrice Kwiatkowski; Flora Ponelle; Sandrine Viala; Maud Privat; Nancy Uhrhammer; Dominique Bernard-Gallon; Frédérique Penault-Llorca; Yves-Jean Bignon; Yannick Bidet
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

5.  Immunohistochemical characterisation of molecular subtypes in endometrial cancer.

Authors:  Sylwia M Łapińska-Szumczyk; Anna M Supernat; Hanna I Majewska; Jacek Gulczyński; Wojciech Biernat; Dariusz Wydra; Anna J Żaczek
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.

Authors:  Carlo Fremd; Mario Hlevnjak; Marc Zapatka; Inka Zoernig; Niels Halama; Nino Fejzibegovic; Verena Thewes; Peter Lichter; Peter Schirmacher; Matthias Kloor; Frederik Marmé; Florian Schütz; Zeynep Kosaloglu; Hans Peter Sinn; Dirk Jäger; Andreas Schneeweiss
Journal:  Breast Care (Basel)       Date:  2018-11-14       Impact factor: 2.860

7.  Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability.

Authors:  Nicola Fusco; Gianluca Lopez; Chiara Corti; Chiara Pesenti; Patrizia Colapietro; Giulia Ercoli; Gabriella Gaudioso; Alice Faversani; Donatella Gambini; Anna Michelotti; Luca Despini; Concetta Blundo; Valentina Vaira; Monica Miozzo; Stefano Ferrero; Silvano Bosari
Journal:  JNCI Cancer Spectr       Date:  2018-12-13

Review 8.  Triple-negative breast cancer: promising prognostic biomarkers currently in development.

Authors:  Jasmine Sukumar; Kelly Gast; Dionisia Quiroga; Maryam Lustberg; Nicole Williams
Journal:  Expert Rev Anticancer Ther       Date:  2021-02       Impact factor: 4.512

Review 9.  The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.

Authors:  Stephanie A Cohen; Anna Leininger
Journal:  Appl Clin Genet       Date:  2014-07-22

10.  Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Authors:  Alexandra Thomas; Eric D Routh; Ashok Pullikuth; Guangxu Jin; Jing Su; Jeff W Chou; Katherine A Hoadley; Cristin Print; Nick Knowlton; Michael A Black; Sandra Demaria; Ena Wang; Davide Bedognetti; Wendell D Jones; Gaurav A Mehta; Michael L Gatza; Charles M Perou; David B Page; Pierre Triozzi; Lance D Miller
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.